Evidence map›Paper›PMID 31679088›Full record

ArticleDigestive diseases and sciences2020

MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C/ZEB1/2 Signal Axis.

Mei Chen, Li-Xiu Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Ubiquitin-conjugating Enzymes in Cancer.International journal of biological sciences · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mei ChenDepartment of Gynecology, Affiliated Hospital of Shaanxi University of Chinese Medicine, No. 2, Weiyang West Road, Xianyang, 712021, Shaanxi, People's Republic of China.
Li-Xiu LiuDepartment of Gynecology, Affiliated Hospital of Shaanxi University of Chinese Medicine, No. 2, Weiyang West Road, Xianyang, 712021, Shaanxi, People's Republic of China. liulixiu_lx@163.com.
Affiliated Hospital of Shaanxi University of Chinese Medicine · CN

Funding

the Science and Technology Project of Xianyang 2017k02-75
6 · The paper itself

Abstract

backgroundAccumulating evidence indicated that miRNAs are important regulators involved in cancer biology.

aimsWe aimed to investigate the biological functions and potentially underlying molecular mechanism of miR-525-5p in CC.

methodsRT-PCR and Western blot assay were performed to detect mRNA and protein expression. Cell proliferation, anoikis resistance, and cell invasion were analyzed.

resultsWe observed that the expression of miR-525-5p was declined in several CC cell lines. Additionally, introduction of miR-525-5p dramatically hampered cell viability, invasiveness, and migration ability through modulating epithelial-to-mesenchymal transition (EMT) marked genes as reflected by the upregulation of E-cadherin, as well as the downregulation of vimentin and N-cadherin. Furthermore, administration of miR-525-5p markedly reduced anchorage-independent growth and anoikis resistance accompanied by a decrease in the expression of anti-apoptotic protein Bcl-2 and an increase in the expression of pro-apoptotic protein Bax, C-caspase 3, and C-PARP1. Most importantly, analysis using publicly available algorithms predicted that UBE2C was a direct and functional target of miR-525-5p. Luciferase assays coupled with RT-PCR and Western blot analysis further verified that miR-525-5p negatively regulated UBE2C expression. Interestingly, miR-525-5p modulated ZEB1/2 expression via targeting UBE2C. Mechanically, administration of UBE2C partially blunted the salutary effects of miR-525-5p on invasive ability, EMT, and anoikis resistance, indicating that miR-525-5p acts as a tumor suppressor in CC largely through repression of UBE2C/ZEB1/2 signaling.

conclusionsTaken together, our data identify a novel signaling axis of miR-525-5p/UBE2C/ZEB1/2 in repressing EMT and anoikis resistance, and likely serve as a potential therapeutic target for CC metastasis and prognosis as well as a therapeutic application.

Indexed as

AnoikisEpithelial-Mesenchymal TransitionFemaleHeLa CellsHumansMicroRNAsNeoplasm MetastasisUbiquitin-Conjugating EnzymesUterine Cervical NeoplasmsZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2MicroRNAsMIRN525 microRNA, humanUBE2C protein, humanUbiquitin-Conjugating EnzymesZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2Anoikis resistanceCervical cancerMetastasisMiR-525-5pUBE2C/ZEB1/2 signal axis

Identifiers

PMID31679088
OpenAlexW2986428325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.